Adjuvant Chemotherapy Use for Medicare Beneficiaries With Stage II Colon Cancer
- 1 October 2002
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 20 (19), 3999-4005
- https://doi.org/10.1200/jco.2002.11.084
Abstract
PURPOSE: Clinical trials have not demonstrated that adjuvant chemotherapy improves survival for patients with resected stage II colon cancer. Nevertheless, patients may receive this treatment despite its uncertain benefit. The objective of this study was to determine the extent to which adjuvant chemotherapy is used for patients with stage II colon cancer. PATIENTS AND METHODS: Using the Surveillance, Epidemiology, and End Results-Medicare linked database, we identified 3,151 patients aged 65 to 75 with resected stage II colon cancer and no adverse prognostic features. The primary outcome was chemotherapy use within 3 months of surgery ascertained from claims submitted to Medicare. Relationships between patient characteristics and adjuvant chemotherapy use were measured and their significance was assessed using multivariable logistic regression. Survival for treated and untreated patients was compared using a Cox model. RESULTS: Twenty-seven percent of patients received chemotherapy during the 3 postoperative months. Younger age at diagnosis, white race, unfavorable tumor grade, and low comorbidity were each associated with a greater likelihood of receiving treatment. Sex, the number of examined lymph nodes in the tumor specimen, the urgency of the surgical admission, and median income was each unrelated to treatment. Five-year survival was 75% for untreated patients and 78% for treated patients. After adjusting for known between-group differences, the hazard ratio for survival associated with adjuvant treatment was 0.91 (95% confidence interval, 0.77 to 1.09). CONCLUSION: A substantial percentage of Medicare beneficiaries with resected stage II colon cancer receive adjuvant chemotherapy despite its uncertain benefit.Keywords
This publication has 16 references indexed in Scilit:
- A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly PatientsNew England Journal of Medicine, 2001
- Mortality Associated With Irinotecan Plus Bolus Fluorouracil/Leucovorin: Summary Findings of an Independent PanelJournal of Clinical Oncology, 2001
- Age and Adjuvant Chemotherapy Use After Surgery for Stage III Colon CancerJNCI Journal of the National Cancer Institute, 2001
- Racial Differences in the Treatment of Early-Stage Lung CancerNew England Journal of Medicine, 1999
- The Tea Leaves of Small TrialsJournal of Clinical Oncology, 1999
- Comparative Efficacy of Adjuvant Chemotherapy in Patients With Dukes' B Versus Dukes' C Colon Cancer: Results From Four National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies (C-01, C-02, C-03, and C-04)Journal of Clinical Oncology, 1999
- Presentation adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectivesJournal of Clinical Epidemiology, 1993
- Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon CarcinomaNew England Journal of Medicine, 1990
- Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic.Journal of Clinical Oncology, 1989
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987